Key result
CYP2J2 regulation and EET signaling modulate diabetes and cardiovascular disease pathophysiology.
-epoxyeicosatrienoic acids (EETs). Although its expression in the liver is low, CYP2J2 is mainly observed in extrahepatic tissues, including the small intestine, pancreas, lung, and heart. Changes in CYP2J2 levels or activity by xenobiotics, disease states, or polymorphisms are proposed to lead to various organ dysfunctions. Several studies have investigated the regulation of CYP2J2 and EET formation in various cell lines and have demonstrated that such regulation is tissue-dependent. In addition, studies linking CYP2J2 polymorphisms to the risk of developing cardiovascular disease (CVD) yielded contradictory results. This review will focus on the mechanisms of regulation of CYP2J2 by inducers, inhibitors, and oxidative stress modeling certain disease states in various cell lines and tissues. The implication of CYP2J2 expression, polymorphisms, activity and, as a result, EET levels in the pathophysiology of diabetes and CVD will also be discussed.
No takes yet. Share an insight, caveat, or question.
Aliwarga et al. (2018) conducted a review in Cardiac Disease and Diabetes. CYP2J2 and EET levels was evaluated. CYP2J2 regulation by inducers, inhibitors, and oxidative stress, alongside its polymorphisms and EET levels, plays a complex role in the pathophysiology of diabetes and cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: